Compare Stocks: SYN, BOLD, KVAC, and INKT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLD Boundless Bio	$2.60 -3.7%	$2.76	$0.96 ▼ $3.16	$65.51M	-0.03	88,570 shs	550,321 shs
INKT MiNK Therapeutics	$12.30 -0.4%	$11.35	$8.48 ▼ $16.93	$61.80M	0.49	13,049 shs	9,980 shs
KVAC Keen Vision Acquisition	$11.51	$11.73	$11.41 ▼ $18.72	$63.37M	-0.04	14,430 shs	N/A
SYN Synthetic Biologics		$0.00	$0.97 ▼ $4.56	$16.16M	1.38	197,338 shs	57,700 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLD Boundless Bio	-3.70%	-7.14%	-11.56%	+1.56%	+127.07%
INKT MiNK Therapeutics	-0.40%	+5.04%	+8.08%	+5.67%	-14.23%
KVAC Keen Vision Acquisition	0.00%	0.00%	0.00%	-6.18%	-1.16%
SYN Synthetic Biologics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLD Boundless Bio	$2.60 -3.7%	$2.76	$0.96 ▼ $3.16	$65.51M	-0.03	88,570 shs	550,321 shs
INKT MiNK Therapeutics	$12.30 -0.4%	$11.35	$8.48 ▼ $16.93	$61.80M	0.49	13,049 shs	9,980 shs
KVAC Keen Vision Acquisition	$11.51	$11.73	$11.41 ▼ $18.72	$63.37M	-0.04	14,430 shs	N/A
SYN Synthetic Biologics		$0.00	$0.97 ▼ $4.56	$16.16M	1.38	197,338 shs	57,700 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLD Boundless Bio	-3.70%	-7.14%	-11.56%	+1.56%	+127.07%
INKT MiNK Therapeutics	-0.40%	+5.04%	+8.08%	+5.67%	-14.23%
KVAC Keen Vision Acquisition	0.00%	0.00%	0.00%	-6.18%	-1.16%
SYN Synthetic Biologics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BOLD Boundless Bio	1.00	Sell	N/A	N/A
INKT MiNK Therapeutics	2.00	Hold	$35.00	184.55% Upside
KVAC Keen Vision Acquisition	2.00	Hold	N/A	N/A
SYN Synthetic Biologics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SYN, BOLD, KVAC, and INKT Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/12/2026	INKT MiNK Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/29/2026	BOLD Boundless Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/29/2026	KVAC Keen Vision Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
7/14/2026	INKT MiNK Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/8/2026	KVAC Keen Vision Acquisition	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
7/6/2026	INKT MiNK Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BOLD Boundless Bio	N/A	N/A	N/A	N/A	$4.41 per share	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	($3.03) per share	N/A
KVAC Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
SYN Synthetic Biologics	N/A	N/A	N/A	N/A	$4.95 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BOLD Boundless Bio	-$58.20M	-$2.86	N/A	N/A	N/A	N/A	-70.89%	-47.37%	N/A
INKT MiNK Therapeutics	-$12.49M	-$2.40	N/A	N/A	N/A	N/A	N/A	-92.37%	11/12/2026 (Estimated)
KVAC Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SYN Synthetic Biologics	-$14.27M	-$1.21	N/A	N/A	N/A	N/A	-26.14%	-22.74%	N/A

Latest SYN, BOLD, KVAC, and INKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	KVAC Keen Vision Acquisition	N/A	$0.08	N/A	$0.08	N/A	N/A
8/13/2026	Q2 2026	INKT MiNK Therapeutics	-$0.60	-$0.62	-$0.02	-$0.62	N/A	N/A
8/7/2026	Q2 2026	BOLD Boundless Bio	N/A	-$1.06	N/A	-$1.06	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BOLD Boundless Bio	N/A	N/A	N/A	N/A	N/A
INKT MiNK Therapeutics	N/A	N/A	N/A	N/A	N/A
KVAC Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A
SYN Synthetic Biologics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BOLD Boundless Bio	N/A	9.48	9.48
INKT MiNK Therapeutics	N/A	1.23	1.23
KVAC Keen Vision Acquisition	N/A	N/A	N/A
SYN Synthetic Biologics	N/A	4.14	4.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BOLD Boundless Bio	N/A
INKT MiNK Therapeutics	2.87%
KVAC Keen Vision Acquisition	51.72%
SYN Synthetic Biologics	74.38%

Insider Ownership

Company	Insider Ownership
BOLD Boundless Bio	23.10%
INKT MiNK Therapeutics	20.40%
KVAC Keen Vision Acquisition	80.20%
SYN Synthetic Biologics	2.15%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BOLD Boundless Bio	28	22.75 million	17.49 million	No Data
INKT MiNK Therapeutics	15	5.10 million	4.06 million	No Data
KVAC Keen Vision Acquisition	N/A	5.51 million	1.09 million	Not Optionable
SYN Synthetic Biologics	16	15.84 million	15.50 million	Not Optionable

SYN, BOLD, KVAC, and INKT Headlines

Recent News About These Companies

SonicStrategy Acquires Additional SYN Tokens and Announces Grant of Stock Options

4 hours ago | newsfilecorp.comN

Tirzepatide Plus Biologics May Improve Outcomes in Psoriatic Arthritis

September 22 at 10:59 PM | rheumatologyadvisor.comR

Cell Line Development: A Story of Innovation in Biologics and Cell-Based Therapies

August 26, 2026 | technologynetworks.comT

Protein Design & Engineering Market Global Report 2026: Evaluating AI Platforms, Rational Design, Directed Evolution, and Strategies of Lonza, Thermo Fisher, GenScript, and ...

August 19, 2026 | finance.yahoo.com

Isto Biologics Strengthens its Bone Graft Substitutes Platform with the Acquisition of NovaBone

August 4, 2026 | finance.yahoo.com

Vivex Biologics Launches VIA Linx™, a Novel Self-Assembling Synthetic Peptide Matrix, Expanding its Portfolio of Advanced Wound Care Solutions

July 21, 2026 | markets.businessinsider.com

Computational design drives new generation of synthetic promoters

March 27, 2026 | drugtargetreview.comD

Gene Synthesis Market Comprehensive Industry Analysis, Trends, and Future Outlook

February 25, 2026 | pharmiweb.comP

6 ways biologics is advancing in spine

February 19, 2026 | beckersspine.comB

Stopping Biologics Before Surgery May Raise Flare Risk in RA

January 27, 2026 | rheumatologyadvisor.comR

Study Shows NanoFuse(R) Superiority: Why Bioactive Glass-DBM Composites Outperform DBM and Bioactive Glass Alone

January 26, 2026 | marketwatch.com

MTF Biologics and Kolosis BIO Launch New Solution for Orthopedic and Spinal Surgeries: Summit Matrix™

January 15, 2026 | uk.finance.yahoo.com

MTF Biologics and Kolosis BIO Launch New Solution for Orthopedic and Spinal Surgeries: Summit Matrix(TM)

January 15, 2026 | marketwatch.com

Asimov and AGC Biologics Team Up to Provide a Cost-Effective, Simplified, and Secure Manufacturing Approach for Viral Vector Production

January 13, 2026 | pharmiweb.comP

4 orthobiologics updates

December 18, 2025 | beckersspine.comB

Exposure to Some DMARDs in Fathers-to-Be Tied to Birth Risks

December 2, 2025 | medscape.comM

Relapse in Juvenile Idiopathic Arthritis After Stopping DMARDs: Key Factors Found

December 1, 2025 | medscape.comM

Constructive Bio and RxCelerate partner to develop biologic therapeutic candidates

November 19, 2025 | businessweekly.co.ukB

RA Onset Age Doesn’t Affect Non-TNF Agents’ Infection Risk

October 29, 2025 | medscape.comM

Aurora Spine Launches New Biologics Portfolio

October 28, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SYN, BOLD, KVAC, and INKT Company Descriptions

Boundless Bio NASDAQ:BOLD

$2.60 -0.10 (-3.70%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$2.60 0.00 (0.00%)

As of 09/24/2026 04:48 PM Eastern

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

MiNK Therapeutics NASDAQ:INKT

$12.30 -0.05 (-0.40%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$12.32 +0.02 (+0.16%)

As of 09/24/2026 07:30 PM Eastern

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Keen Vision Acquisition NASDAQ:KVAC

$11.51 0.00 (0.00%)

As of 09/23/2026

Keen Vision Acquisition Corporation does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, and related business combination with one or more businesses or entities. It also intends to focus on businesses in the biotechnology, consumer goods, and agriculture sectors. The company was incorporated in 2021 and is based in Summit, New Jersey.

Synthetic Biologics NYSEAMERICAN:SYN

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SYN, BOLD, KVAC, and INKT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SYN, BOLD, KVAC, and INKT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SYN, BOLD, KVAC, and INKT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SYN, BOLD, KVAC, and INKT Company Descriptions

Boundless Bio NASDAQ:BOLD

MiNK Therapeutics NASDAQ:INKT

Keen Vision Acquisition NASDAQ:KVAC

Synthetic Biologics NYSEAMERICAN:SYN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SYN, BOLD, KVAC, and INKT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SYN, BOLD, KVAC, and INKT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SYN, BOLD, KVAC, and INKT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SYN, BOLD, KVAC, and INKT Company Descriptions

Boundless Bio NASDAQ:BOLD

MiNK Therapeutics NASDAQ:INKT

Keen Vision Acquisition NASDAQ:KVAC

Synthetic Biologics NYSEAMERICAN:SYN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools